micafungin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antifungal antibiotics 1798 235114-32-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mycamine
  • micafungin
  • micafungin sodium
  • FK-463
  • FK463
A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.
  • Molecular weight: 1270.28
  • Formula: C56H71N9O23S
  • CLOGP: -1.99
  • LIPINSKI: 3
  • HAC: 32
  • HDO: 16
  • TPSA: 510.14
  • ALOGS: -3.77
  • ROTB: 18

Drug dosage:

DoseUnitRoute
0.10 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.30 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.21 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.17 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 16 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 100 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
March 16, 2005 FDA FUJISAWA HLTHCARE
April 25, 2008 EMA Astellas Pharma Europe B.V.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 365.41 27.72 218 9131 158131 90460967
Aplastic anaemia 218.93 27.72 73 9276 13196 90605902
Pre-engraftment immune reaction 193.81 27.72 32 9317 236 90618862
Human herpesvirus 6 infection 173.49 27.72 45 9304 3387 90615711
Encephalitis viral 167.94 27.72 39 9310 1850 90617248
Multiple organ dysfunction syndrome 164.80 27.72 97 9252 68239 90550859
Pulmonary mucormycosis 137.21 27.72 27 9322 573 90618525
Drug ineffective 131.82 27.72 374 8975 1383924 89235174
Sepsis 130.73 27.72 124 9225 179690 90439408
Acute graft versus host disease 126.85 27.72 39 9310 5429 90613669
Pneumonia fungal 121.21 27.72 40 9309 6991 90612107
Mucormycosis 118.00 27.72 34 9315 3787 90615311
Aspergillus infection 115.21 27.72 43 9306 10780 90608318
Fungaemia 113.30 27.72 32 9317 3318 90615780
Septic shock 106.62 27.72 80 9269 84080 90535018
Bronchopulmonary aspergillosis 105.88 27.72 41 9308 11357 90607741
Cytomegalovirus test positive 102.25 27.72 30 9319 3561 90615537
Bacterial sepsis 100.94 27.72 32 9317 4923 90614175
Thrombotic microangiopathy 96.33 27.72 42 9307 15701 90603397
Acute graft versus host disease in skin 89.84 27.72 29 9320 4727 90614371
Cytomegalovirus infection 86.53 27.72 46 9303 26556 90592542
Systemic candida 84.62 27.72 28 9321 4931 90614167
Hepatic function abnormal 79.47 27.72 53 9296 46235 90572863
Haemophagocytic lymphohistiocytosis 77.86 27.72 36 9313 15423 90603675
Off label use 77.65 27.72 269 9080 1101983 89517115
Systemic mycosis 77.02 27.72 20 9329 1510 90617588
Acute myeloid leukaemia recurrent 75.73 27.72 21 9328 2036 90617062
Cytomegalovirus viraemia 72.99 27.72 28 9321 7558 90611540
Respiratory failure 71.72 27.72 74 9275 118344 90500754
Disseminated intravascular coagulation 66.55 27.72 36 9313 21502 90597596
Gastrointestinal fungal infection 66.23 27.72 14 9335 428 90618670
Product use in unapproved indication 65.27 27.72 121 9228 336115 90282983
Liver abscess 64.74 27.72 21 9328 3475 90615623
Pathogen resistance 64.20 27.72 26 9323 8089 90611009
Meningoencephalitis herpetic 63.52 27.72 17 9332 1442 90617656
Engraft failure 62.60 27.72 13 9336 364 90618734
Mucosal inflammation 62.53 27.72 50 9299 57575 90561523
Klebsiella infection 58.24 27.72 26 9323 10271 90608827
Graft versus host disease 57.32 27.72 24 9325 8120 90610978
Fungal infection 57.22 27.72 42 9307 42619 90576479
Enterococcal sepsis 57.21 27.72 16 9333 1600 90617498
Fatigue 57.10 27.72 24 9325 1153999 89465099
Trichosporon infection 56.70 27.72 12 9337 369 90618729
Aspartate aminotransferase increased 56.40 27.72 61 9288 102876 90516222
Candida infection 56.06 27.72 38 9311 34019 90585079
Sinus polyp 55.45 27.72 12 9337 411 90618687
Neutropenia 54.09 27.72 89 9260 224815 90394283
Cytokine release syndrome 52.80 27.72 34 9315 27939 90591159
Arthralgia 51.89 27.72 9 9340 778513 89840585
Pyrexia 49.58 27.72 165 9184 660320 89958778
Acute myeloid leukaemia 48.90 27.72 29 9320 20611 90598487
Pain 48.79 27.72 21 9328 996320 89622778
Weissella infection 48.64 27.72 7 9342 17 90619081
Renal impairment 48.42 27.72 57 9292 105364 90513734
Hypoalbuminaemia 47.52 27.72 26 9323 15871 90603227
Nasal abscess 46.14 27.72 9 9340 182 90618916
Platelet count decreased 45.44 27.72 63 9286 136906 90482192
Plasma cell leukaemia 43.44 27.72 12 9337 1146 90617952
Enterococcal infection 43.35 27.72 21 9328 9970 90609128
Alanine aminotransferase increased 43.15 27.72 57 9292 118281 90500817
Enterobacter infection 41.74 27.72 14 9335 2569 90616529
Drug ineffective for unapproved indication 40.95 27.72 42 9307 66602 90552496
Acute graft versus host disease in intestine 40.56 27.72 13 9336 2070 90617028
Acute respiratory distress syndrome 40.19 27.72 29 9320 28657 90590441
Venoocclusive liver disease 39.97 27.72 17 9332 5976 90613122
Pleural effusion 39.38 27.72 53 9296 111938 90507160
Cryptosporidiosis infection 38.95 27.72 9 9340 417 90618681
Staphylococcal sepsis 38.55 27.72 19 9330 9364 90609734
Biloma 38.25 27.72 7 9342 99 90618999
Periostitis 38.03 27.72 9 9340 463 90618635
Mucosal erosion 37.93 27.72 12 9337 1833 90617265
Shock 37.84 27.72 28 9321 28750 90590348
Post transplant lymphoproliferative disorder 37.56 27.72 17 9332 6932 90612166
Agranulocytosis 37.17 27.72 30 9319 34972 90584126
Alopecia 37.00 27.72 4 9345 495067 90124031
Encephalitis Japanese B 36.24 27.72 6 9343 45 90619053
Hypersensitivity 35.76 27.72 3 9346 454674 90164424
Abdominal discomfort 35.31 27.72 4 9345 477324 90141774
Chronic graft versus host disease 35.30 27.72 14 9335 4125 90614973
Pulmonary trichosporonosis 35.07 27.72 6 9343 56 90619042
Oral fungal infection 34.58 27.72 13 9336 3319 90615779
Malaise 34.45 27.72 9 9340 585977 90033121
Stenotrophomonas infection 34.21 27.72 12 9337 2517 90616581
Fungal oesophagitis 33.44 27.72 9 9340 780 90618318
Acute lymphocytic leukaemia recurrent 33.35 27.72 12 9337 2709 90616389
Transplant rejection 33.06 27.72 19 9330 12739 90606359
Varicella zoster virus infection 32.67 27.72 13 9336 3864 90615234
Encephalitis fungal 32.64 27.72 6 9343 87 90619011
Drug intolerance 32.48 27.72 4 9345 447587 90171511
Headache 32.48 27.72 25 9324 862721 89756377
Bacteraemia 32.28 27.72 23 9326 22277 90596821
Pancytopenia 32.17 27.72 50 9299 120213 90498885
Escherichia infection 31.68 27.72 20 9329 15875 90603223
Cerebral haemorrhage 31.29 27.72 27 9322 34495 90584603
Fall 31.12 27.72 6 9343 481804 90137294
Acute febrile neutrophilic dermatosis 30.26 27.72 12 9337 3533 90615565
Neutrophil count decreased 30.08 27.72 37 9312 71495 90547603
Epstein-Barr virus associated lymphoproliferative disorder 29.85 27.72 11 9338 2656 90616442
Weight increased 29.68 27.72 4 9345 417923 90201175
Bacteriuria 29.66 27.72 9 9340 1197 90617901
Fluorosis 29.55 27.72 6 9343 150 90618948
Polyomavirus viraemia 28.88 27.72 9 9340 1308 90617790
Aspergillus test positive 28.81 27.72 7 9342 403 90618695
Rash morbilliform 28.78 27.72 12 9337 4017 90615081
Human herpesvirus 6 encephalitis 28.76 27.72 7 9342 406 90618692
Scedosporium infection 28.43 27.72 8 9341 818 90618280
Asthenia 28.11 27.72 10 9339 533741 90085357
Drug resistance 27.97 27.72 24 9325 30425 90588673
Blood bilirubin increased 27.80 27.72 28 9321 43442 90575656

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Aplastic anaemia 316.19 20.32 132 15702 12252 42593249
Febrile neutropenia 252.93 20.32 327 15507 185376 42420125
Lymphoid tissue hypoplasia 191.99 20.32 48 15786 830 42604671
Thymus hypoplasia 187.87 20.32 47 15787 815 42604686
Multiple organ dysfunction syndrome 186.53 20.32 204 15630 96831 42508670
Fungal infection 179.52 20.32 104 15730 19618 42585883
Bronchopulmonary aspergillosis 175.64 20.32 102 15732 19327 42586174
Cytomegalovirus viraemia 163.62 20.32 79 15755 10298 42595203
Aspergillus infection 150.76 20.32 86 15748 15751 42589750
Acute graft versus host disease in skin 149.63 20.32 67 15767 7357 42598144
Disseminated aspergillosis 142.66 20.32 44 15790 1686 42603815
Drug ineffective 141.65 20.32 532 15302 629665 41975836
Disseminated intravascular coagulation 104.47 20.32 81 15753 24713 42580788
Product use in unapproved indication 101.20 20.32 216 15618 184240 42421261
Candida infection 100.76 20.32 75 15759 21535 42583966
Acute graft versus host disease in intestine 97.04 20.32 41 15793 3910 42601591
Herpes simplex oesophagitis 91.81 20.32 21 15813 243 42605258
Mucosal inflammation 91.57 20.32 102 15732 49272 42556229
Acute graft versus host disease 81.90 20.32 46 15788 8169 42597332
Fatigue 78.51 20.32 32 15802 435609 42169892
Venoocclusive liver disease 77.28 20.32 48 15786 10254 42595247
Graft versus host disease 76.75 20.32 52 15782 12873 42592628
Mucormycosis 73.94 20.32 41 15793 7102 42598399
Trichosporon infection 73.39 20.32 23 15811 929 42604572
Pyrexia 72.91 20.32 314 15520 393728 42211773
Clostridium difficile colitis 71.71 20.32 61 15773 21191 42584310
Corynebacterium bacteraemia 69.92 20.32 15 15819 126 42605375
Cytomegalovirus test positive 68.42 20.32 33 15801 4286 42601215
Enterococcus test positive 67.83 20.32 25 15809 1660 42603841
Cerebral aspergillosis 66.53 20.32 25 15809 1752 42603749
Respiratory failure 65.54 20.32 146 15688 127986 42477515
Fungaemia 65.41 20.32 29 15805 3107 42602394
Acute myeloid leukaemia recurrent 65.39 20.32 30 15804 3482 42602019
Fusarium infection 65.14 20.32 24 15810 1592 42603909
Sepsis 63.51 20.32 190 15644 199144 42406357
Bacterial infection 63.01 20.32 64 15770 27815 42577686
Systemic mycosis 62.74 20.32 26 15808 2361 42603140
Systemic candida 61.92 20.32 33 15801 5286 42600215
Pre-engraftment immune reaction 61.12 20.32 14 15820 163 42605338
Enterococcal infection 61.12 20.32 44 15790 11995 42593506
Disseminated mucormycosis 61.06 20.32 22 15812 1369 42604132
Septic shock 59.21 20.32 115 15719 91557 42513944
Lymphopenia 59.04 20.32 55 15779 21508 42583993
Geotrichum infection 57.57 20.32 17 15817 560 42604941
Encephalitis viral 55.41 20.32 21 15813 1507 42603994
Cystitis haemorrhagic 54.59 20.32 34 15800 7295 42598206
Anti factor V antibody 53.11 20.32 14 15820 301 42605200
Dizziness 52.35 20.32 14 15820 249240 42356261
Cytomegalovirus infection 51.89 20.32 62 15772 32244 42573257
Human herpesvirus 6 infection 51.54 20.32 23 15811 2502 42602999
Cytokine release syndrome 50.53 20.32 72 15762 44455 42561046
Acute graft versus host disease in liver 50.36 20.32 21 15813 1937 42603564
Tumour lysis syndrome 50.16 20.32 51 15783 22180 42583321
Off label use 48.19 20.32 402 15432 637933 41967568
Fungal endocarditis 47.74 20.32 14 15820 450 42605051
Product dose omission issue 45.59 20.32 3 15831 154362 42451139
Pneumonia fungal 45.45 20.32 33 15801 9113 42596388
Cystitis viral 44.78 20.32 17 15817 1225 42604276
Fall 44.17 20.32 16 15818 234504 42370997
Enterococcal bacteraemia 44.13 20.32 21 15813 2646 42602855
Hepatic function abnormal 43.91 20.32 73 15761 51494 42554007
Cerebral ventricle collapse 43.08 20.32 10 15824 124 42605377
Glomerulosclerosis 42.83 20.32 15 15819 859 42604642
Drug resistance 42.78 20.32 58 15776 34190 42571311
Chronic graft versus host disease 42.49 20.32 27 15807 5998 42599503
Bacteraemia 40.11 20.32 48 15786 24992 42580509
Staphylococcal sepsis 38.98 20.32 33 15801 11381 42594120
Botulism 38.06 20.32 10 15824 212 42605289
Acute myeloid leukaemia 37.87 20.32 44 15790 22212 42583289
Blood beta-D-glucan increased 37.52 20.32 12 15822 518 42604983
Mycotic endophthalmitis 37.46 20.32 10 15824 226 42605275
Arthralgia 36.98 20.32 15 15819 205223 42400278
Gastrointestinal mucormycosis 36.75 20.32 11 15823 380 42605121
Neutropenia 35.97 20.32 158 15676 199273 42406228
Graft versus host disease in skin 35.87 20.32 23 15811 5189 42600312
Pain 35.13 20.32 24 15810 244824 42360677
Myocardial infarction 34.93 20.32 3 15831 124006 42481495
Acute respiratory distress syndrome 34.61 20.32 49 15785 30059 42575442
Gastrointestinal mucosal disorder 34.19 20.32 11 15823 484 42605017
Pruritus 33.67 20.32 14 15820 188757 42416744
Dyspnoea 33.25 20.32 72 15762 442549 42162952
Haemophagocytic lymphohistiocytosis 32.64 20.32 37 15797 18185 42587316
Candida sepsis 32.20 20.32 14 15820 1431 42604070
Weight decreased 31.71 20.32 19 15815 207929 42397572
Somnolence 31.39 20.32 7 15827 141098 42464403
Graft versus host disease in gastrointestinal tract 31.26 20.32 21 15813 5122 42600379
Hypogonadism 30.88 20.32 16 15818 2418 42603083
Depression 30.55 20.32 3 15831 111360 42494141
Infection 30.25 20.32 101 15733 111967 42493534
Idiopathic pneumonia syndrome 30.23 20.32 10 15824 481 42605020
Platelet count decreased 29.85 20.32 116 15718 138465 42467036
Cholestatic liver injury 29.64 20.32 18 15816 3691 42601810
Cytomegalovirus enterocolitis 29.52 20.32 13 15821 1370 42604131
Sinusitis fungal 29.42 20.32 11 15823 760 42604741
Klebsiella infection 29.28 20.32 28 15806 11304 42594197
Cellulitis 29.02 20.32 68 15766 61517 42543984
Device related sepsis 28.87 20.32 18 15816 3869 42601632
Drug ineffective for unapproved indication 28.66 20.32 57 15777 46106 42559395
Immunosuppressant drug level increased 27.74 20.32 23 15811 7708 42597793
Graft versus host disease in liver 27.41 20.32 13 15821 1626 42603875
Aspartate aminotransferase increased 26.84 20.32 76 15758 77087 42528414
Nephropathy toxic 26.51 20.32 32 15802 16806 42588695
Kidney fibrosis 26.47 20.32 15 15819 2707 42602794
Malaise 26.37 20.32 24 15810 212132 42393369
Device related infection 26.32 20.32 35 15799 20244 42585257
Venoocclusive disease 26.26 20.32 17 15817 3898 42601603
Disseminated cryptococcosis 25.42 20.32 13 15821 1912 42603589
Blood pressure increased 24.91 20.32 4 15830 101924 42503577
Thrombotic microangiopathy 24.77 20.32 29 15805 14753 42590748
Engraft failure 24.76 20.32 9 15825 574 42604927
Enterococcal sepsis 24.69 20.32 13 15821 2031 42603470
Pulmonary embolism 24.54 20.32 7 15827 119605 42485896
Pseudomembranous colitis 24.51 20.32 15 15819 3118 42602383
Headache 24.32 20.32 32 15802 239337 42366164
Asthenia 24.23 20.32 42 15792 280751 42324750
Delayed graft function 24.23 20.32 14 15820 2621 42602880
Nausea 24.00 20.32 72 15762 396727 42208774
Mucosal disorder 23.93 20.32 13 15821 2161 42603340
Necrotising oesophagitis 23.59 20.32 10 15824 961 42604540
Rhinocerebral mucormycosis 23.29 20.32 9 15825 681 42604820
Engraftment syndrome 23.17 20.32 11 15823 1379 42604122
Renal failure 23.00 20.32 110 15724 143616 42461885
Infection in an immunocompromised host 22.77 20.32 10 15824 1047 42604454
Renal impairment 22.69 20.32 91 15743 110137 42495364
Pseudomonal sepsis 22.64 20.32 16 15818 4233 42601268
Pain in extremity 22.61 20.32 14 15820 150590 42454911
Anxiety 22.44 20.32 8 15826 118552 42486949
Alanine aminotransferase increased 22.38 20.32 78 15756 88328 42517173
Ophthalmic vein thrombosis 22.34 20.32 5 15829 52 42605449
Chest pain 22.33 20.32 12 15822 139518 42465983
Functional gastrointestinal disorder 22.30 20.32 13 15821 2475 42603026
Bacterial toxaemia 22.25 20.32 6 15828 141 42605360
Stenotrophomonas infection 22.21 20.32 15 15819 3689 42601812
Minimum inhibitory concentration increased 22.05 20.32 4 15830 12 42605489
Scedosporium infection 21.97 20.32 11 15823 1547 42603954
Toxicity to various agents 21.91 20.32 32 15802 229104 42376397
Pathogen resistance 21.79 20.32 24 15810 11426 42594075
Blast cell count increased 21.67 20.32 10 15824 1175 42604326
Staphylococcal infection 21.61 20.32 45 15789 37598 42567903
Dehydration 21.53 20.32 13 15821 141754 42463747
Hyperbilirubinaemia 21.41 20.32 32 15802 20603 42584898
Nasopharyngitis 21.20 20.32 3 15831 83993 42521508
Acute lymphocytic leukaemia 20.83 20.32 14 15820 3417 42602084
Haemorrhagic necrotic pancreatitis 20.70 20.32 6 15828 185 42605316

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 573.70 22.18 505 23555 316262 110248977
Aplastic anaemia 543.58 22.18 203 23857 24105 110541134
Multiple organ dysfunction syndrome 329.54 22.18 269 23791 151441 110413798
Drug ineffective 305.26 22.18 867 23193 1519673 109045566
Bronchopulmonary aspergillosis 269.32 22.18 131 23929 29732 110535507
Aspergillus infection 257.27 22.18 121 23939 25495 110539744
Fungal infection 247.43 22.18 148 23912 50658 110514581
Cytomegalovirus viraemia 245.79 22.18 105 23955 17659 110547580
Pre-engraftment immune reaction 236.24 22.18 46 24014 413 110564826
Lymphoid tissue hypoplasia 216.66 22.18 54 24006 1611 110563628
Thymus hypoplasia 210.97 22.18 53 24007 1634 110563605
Disseminated aspergillosis 209.23 22.18 57 24003 2423 110562816
Encephalitis viral 207.34 22.18 59 24001 2948 110562291
Human herpesvirus 6 infection 192.19 22.18 67 23993 6514 110558725
Sepsis 188.01 22.18 289 23771 327057 110238182
Mucormycosis 184.89 22.18 74 23986 10554 110554685
Product use in unapproved indication 180.07 22.18 337 23723 447040 110118199
Acute graft versus host disease 174.44 22.18 75 23985 12806 110552433
Mucosal inflammation 158.93 22.18 146 23914 95995 110469244
Fungaemia 155.09 22.18 56 24004 6030 110559209
Disseminated intravascular coagulation 154.99 22.18 102 23958 41184 110524055
Acute graft versus host disease in skin 150.27 22.18 64 23996 10676 110554563
Septic shock 145.02 22.18 175 23885 157353 110407886
Candida infection 141.06 22.18 102 23958 47907 110517332
Cytomegalovirus infection 140.53 22.18 107 23953 54337 110510902
Pneumonia fungal 139.87 22.18 67 23993 14687 110550552
Trichosporon infection 133.95 22.18 35 24025 1265 110563974
Systemic candida 131.53 22.18 57 24003 9917 110555322
Respiratory failure 130.39 22.18 195 23865 215137 110350102
Systemic mycosis 127.46 22.18 43 24017 3786 110561453
Fatigue 125.67 22.18 54 24006 1215904 109349335
Pulmonary mucormycosis 120.97 22.18 36 24024 2107 110563132
Acute myeloid leukaemia recurrent 118.75 22.18 44 24016 5095 110560144
Acute graft versus host disease in intestine 118.37 22.18 45 24015 5594 110559645
Pyrexia 113.78 22.18 440 23620 897825 109667414
Hepatic function abnormal 112.70 22.18 117 23943 89178 110476061
Venoocclusive liver disease 111.48 22.18 58 24002 15149 110550090
Cytokine release syndrome 108.89 22.18 103 23957 70203 110495036
Enterococcal infection 106.09 22.18 62 23998 20304 110544935
Arthralgia 103.14 22.18 22 24038 779610 109785629
Graft versus host disease 102.60 22.18 59 24001 18747 110546492
Bacterial infection 100.53 22.18 82 23978 45954 110519285
Pain 99.19 22.18 42 24018 954913 109610326
Cytomegalovirus test positive 98.67 22.18 42 24018 6994 110558245
Bacterial sepsis 97.77 22.18 47 24013 10379 110554860
Off label use 95.78 22.18 604 23456 1499581 109065658
Clostridium difficile colitis 95.64 22.18 78 23982 43700 110521539
Herpes simplex oesophagitis 91.20 22.18 21 24039 443 110564796
Cerebral aspergillosis 89.22 22.18 29 24031 2273 110562966
Haemophagocytic lymphohistiocytosis 85.80 22.18 64 23996 31495 110533744
Platelet count decreased 85.58 22.18 168 23892 230275 110334964
Tumour lysis syndrome 84.94 22.18 63 23997 30738 110534501
Pathogen resistance 84.73 22.18 51 24009 17621 110547618
Neutropenia 84.39 22.18 224 23836 374396 110190843
Klebsiella infection 83.87 22.18 53 24007 19956 110545283
Acute myeloid leukaemia 79.27 22.18 66 23994 38044 110527195
Drug resistance 78.65 22.18 78 23982 56296 110508943
Fusarium infection 76.27 22.18 27 24033 2744 110562495
Dizziness 75.19 22.18 29 24031 698164 109867075
Headache 75.13 22.18 50 24010 882327 109682912
Acute respiratory distress syndrome 74.95 22.18 74 23986 53124 110512115
Thrombotic microangiopathy 74.56 22.18 57 24003 29092 110536147
Joint swelling 73.86 22.18 6 24054 442839 110122400
Nasopharyngitis 72.88 22.18 3 24057 394358 110170881
Aspartate aminotransferase increased 72.40 22.18 127 23933 159809 110405430
Corynebacterium bacteraemia 72.25 22.18 15 24045 191 110565048
Meningoencephalitis herpetic 72.23 22.18 25 24035 2377 110562862
Lymphopenia 72.23 22.18 64 23996 40106 110525133
Enterococcus test positive 71.29 22.18 26 24034 2878 110562361
Bacteraemia 71.22 22.18 65 23995 42325 110522914
Fall 70.24 22.18 22 24038 603460 109961779
Renal impairment 69.47 22.18 137 23923 188308 110376931
Malaise 68.94 22.18 30 24030 671789 109893450
Peripheral swelling 65.94 22.18 6 24054 404028 110161211
Enterococcal sepsis 60.87 22.18 24 24036 3288 110561951
Mycotic endophthalmitis 60.71 22.18 15 24045 431 110564808
Alopecia 60.65 22.18 5 24055 364748 110200491
Staphylococcal sepsis 60.38 22.18 41 24019 17413 110547826
Anti factor V antibody 60.24 22.18 14 24046 308 110564931
Disseminated mucormycosis 59.83 22.18 21 24039 2081 110563158
Drug ineffective for unapproved indication 59.14 22.18 91 23969 102747 110462492
Alanine aminotransferase increased 58.77 22.18 126 23934 183647 110381592
Geotrichum infection 58.29 22.18 18 24042 1194 110564045
Product dose omission issue 57.65 22.18 3 24057 321779 110243460
Gastrointestinal fungal infection 56.94 22.18 16 24044 763 110564476
Cystitis viral 54.84 22.18 18 24042 1455 110563784
Drug intolerance 54.64 22.18 11 24049 406501 110158738
Enterococcal bacteraemia 53.97 22.18 24 24036 4437 110560802
Acute graft versus host disease in liver 53.78 22.18 20 24040 2339 110562900
Hypoalbuminaemia 53.76 22.18 47 24013 28927 110536312
Dyspnoea 53.34 22.18 100 23960 1106772 109458467
Weight increased 53.09 22.18 13 24047 419631 110145608
Chronic graft versus host disease 52.47 22.18 30 24030 9427 110555812
Blood bilirubin increased 52.03 22.18 73 23987 75899 110489340
Drug hypersensitivity 52.02 22.18 17 24043 454073 110111166
Fungal endocarditis 51.37 22.18 15 24045 821 110564418
Asthenia 50.98 22.18 45 24015 688954 109876285
Neutrophil count decreased 50.82 22.18 93 23967 120848 110444391
Pruritus 50.72 22.18 32 24028 581528 109983711
Graft versus host disease in skin 50.72 22.18 28 24032 8226 110557013
Cystitis haemorrhagic 50.32 22.18 32 24028 12177 110553062
Abdominal discomfort 50.21 22.18 12 24048 393846 110171393
Renal failure 49.45 22.18 134 23926 226440 110338799
Scedosporium infection 49.38 22.18 19 24041 2439 110562800
Escherichia infection 49.02 22.18 41 24019 23775 110541464
Graft versus host disease in gastrointestinal tract 48.55 22.18 28 24032 8940 110556299
Engraft failure 47.16 22.18 14 24046 812 110564427
Cytomegalovirus enterocolitis 47.14 22.18 18 24042 2263 110562976
Liver abscess 46.86 22.18 26 24034 7713 110557526
Device related infection 46.66 22.18 50 24010 39469 110525770
Hypersensitivity 46.48 22.18 15 24045 403983 110161256
White blood cell count decreased 46.44 22.18 132 23928 229258 110335981
Depression 46.10 22.18 7 24053 317328 110247911
Pleural effusion 45.90 22.18 112 23948 177597 110387642
Acute respiratory failure 45.25 22.18 68 23992 75192 110490047
Cerebral ventricle collapse 45.09 22.18 10 24050 177 110565062
Pain in extremity 45.01 22.18 25 24035 487093 110078146
Immune effector cell-associated neurotoxicity syndrome 44.76 22.18 32 24028 14750 110550489
Disseminated cryptococcosis 44.48 22.18 18 24042 2639 110562600
Blood beta-D-glucan increased 43.53 22.18 13 24047 770 110564469
Musculoskeletal stiffness 43.45 22.18 5 24055 279817 110285422
Weissella infection 43.41 22.18 7 24053 17 110565222
Hypoaesthesia 43.28 22.18 8 24052 314215 110251024
Engraftment syndrome 42.65 22.18 16 24044 1916 110563323
Candida sepsis 42.59 22.18 18 24042 2943 110562296
Graft versus host disease in liver 42.30 22.18 17 24043 2448 110562791
Hypogonadism 42.16 22.18 16 24044 1978 110563261
Hyperbilirubinaemia 41.96 22.18 42 24018 30629 110534610
Stenotrophomonas infection 41.95 22.18 22 24038 5836 110559403
Idiopathic pneumonia syndrome 41.93 22.18 13 24047 874 110564365
Staphylococcal infection 41.77 22.18 63 23997 69881 110495358
Brain abscess 41.68 22.18 23 24037 6751 110558488
Sinus polyp 41.06 22.18 12 24048 659 110564580
Pseudomonal sepsis 40.53 22.18 25 24035 9021 110556218
Mobility decreased 40.17 22.18 3 24057 237419 110327820
Nephropathy toxic 40.14 22.18 39 24021 27439 110537800
Transplant rejection 39.95 22.18 37 24023 24530 110540709
Gastrointestinal mucormycosis 39.88 22.18 12 24048 729 110564510
Cholestatic liver injury 39.85 22.18 23 24037 7353 110557886
Contraindicated product administered 39.65 22.18 4 24056 248263 110316976
Staphylococcal bacteraemia 39.13 22.18 31 24029 16657 110548582
Nasal abscess 38.99 22.18 9 24051 192 110565047
Urticaria 38.19 22.18 11 24049 318846 110246393
Paraesthesia 38.16 22.18 7 24053 276514 110288725
Blast cell count increased 37.76 22.18 14 24046 1623 110563616
Pneumonia 37.71 22.18 322 23738 876392 109688847
Glomerulosclerosis 37.28 22.18 13 24047 1264 110563975
Swelling 37.04 22.18 15 24045 351026 110214213
Immunosuppressant drug level increased 36.93 22.18 26 24034 11698 110553541
Platelet transfusion 36.66 22.18 16 24044 2830 110562409
Contusion 36.65 22.18 4 24056 233357 110331882
Acute kidney injury 36.62 22.18 250 23810 635180 109930059
Acute lymphocytic leukaemia recurrent 36.57 22.18 20 24040 5767 110559472
Device related sepsis 36.48 22.18 22 24038 7625 110557614
Wheezing 36.23 22.18 6 24054 255224 110310015
Systemic lupus erythematosus 36.06 22.18 6 24054 254332 110310907
Anxiety 35.99 22.18 15 24045 345063 110220176
Pulmonary trichosporonosis 35.73 22.18 7 24053 65 110565174
Mucosal disorder 35.71 22.18 18 24042 4399 110560840
Rhinocerebral mucormycosis 35.09 22.18 13 24047 1504 110563735
Botulism 34.62 22.18 10 24050 527 110564712
Muscle spasms 34.42 22.18 9 24051 278148 110287091
Pancytopenia 34.33 22.18 112 23948 209501 110355738
Cellulitis 34.22 22.18 81 23979 125935 110439304
Pneumonia klebsiella 34.03 22.18 20 24040 6612 110558627
Nausea 34.02 22.18 146 23914 1235544 109329695
Chest pain 33.77 22.18 20 24040 376355 110188884
Mucosal erosion 33.55 22.18 15 24045 2809 110562430
Delayed graft function 33.40 22.18 17 24043 4240 110560999
Pancreatitis acute 32.78 22.18 52 24008 60222 110505017
Venoocclusive disease 32.19 22.18 19 24041 6331 110558908
Weight decreased 31.75 22.18 33 24027 468024 110097215
Adenovirus infection 31.46 22.18 23 24037 10971 110554268
Pericarditis 31.43 22.18 5 24055 219109 110346130
Acute lymphocytic leukaemia 31.21 22.18 18 24042 5747 110559492
Plasma cell leukaemia 31.06 22.18 13 24047 2075 110563164
Necrotising oesophagitis 30.83 22.18 12 24048 1588 110563651
Periostitis 30.41 22.18 10 24050 813 110564426
Hepatic failure 30.32 22.18 54 24006 68685 110496554
Shock 30.21 22.18 47 24013 53541 110511698
Maternal exposure during pregnancy 30.13 22.18 9 24051 254874 110310365
Epstein-Barr virus infection 30.04 22.18 28 24032 18710 110546529
Oesophagitis 29.87 22.18 34 24026 28681 110536558
Gastrointestinal mucosal disorder 29.72 22.18 11 24049 1269 110563970
Encephalitis Japanese B 29.54 22.18 6 24054 68 110565171
Blood cholesterol increased 29.45 22.18 3 24057 184782 110380457
Organ failure 28.66 22.18 16 24044 4801 110560438
Confusional state 28.58 22.18 36 24024 468644 110096595
Enterobacter infection 28.45 22.18 17 24043 5794 110559445
Acute febrile neutrophilic dermatosis 28.30 22.18 16 24044 4920 110560319
Rash morbilliform 28.27 22.18 19 24041 7932 110557307
Dyspepsia 28.21 22.18 4 24056 190961 110374278
Toxic epidermal necrolysis 28.21 22.18 47 24013 56680 110508559
Injection site pain 28.06 22.18 3 24057 177919 110387320
Blood urea increased 27.96 22.18 46 24014 54911 110510328
Viral haemorrhagic cystitis 27.92 22.18 14 24046 3385 110561854
Human herpesvirus 6 encephalitis 27.80 22.18 10 24050 1064 110564175
Bone marrow failure 27.54 22.18 47 24013 57801 110507438
Dysbiosis 27.50 22.18 12 24048 2120 110563119
Pseudomonas infection 27.32 22.18 32 24028 27821 110537418
Blood pressure increased 27.31 22.18 11 24049 258362 110306877
Pulmonary haemorrhage 27.18 22.18 25 24035 16431 110548808
Memory impairment 27.14 22.18 5 24055 196939 110368300
Impaired healing 27.09 22.18 5 24055 196712 110368527
Biloma 27.00 22.18 7 24053 245 110564994
Musculoskeletal pain 26.65 22.18 4 24056 183019 110382220
Blood lactate dehydrogenase increased 26.56 22.18 40 24020 44294 110520945
Back pain 26.48 22.18 25 24035 370971 110194268
Leukaemia recurrent 26.02 22.18 13 24047 3118 110562121
Neutropenic colitis 25.67 22.18 18 24042 8047 110557192
Proctalgia 25.64 22.18 22 24038 13200 110552039
Gamma-glutamyltransferase increased 25.56 22.18 47 24013 61262 110503977
Sleep disorder 25.40 22.18 6 24054 198638 110366601
Lymphocyte count decreased 25.28 22.18 45 24015 57198 110508041
Blister 25.17 22.18 9 24051 227367 110337872
Hypokalaemia 25.09 22.18 92 23968 182356 110382883
Drug eruption 24.76 22.18 43 24017 53616 110511623
Sinusitis fungal 24.71 22.18 12 24048 2708 110562531
Infusion related reaction 24.59 22.18 28 24032 381134 110184105
Pseudomembranous colitis 24.48 22.18 16 24044 6375 110558864
Bacterial toxaemia 24.43 22.18 6 24054 168 110565071
Oral fungal infection 24.37 22.18 14 24046 4438 110560801
Abdominal pain upper 24.36 22.18 24 24036 349087 110216152
Toxicity to various agents 24.33 22.18 42 24018 480513 110084726
Aspergillus test positive 24.29 22.18 9 24051 1041 110564198
Cryptococcal meningoencephalitis 23.98 22.18 7 24053 383 110564856
Posterior reversible encephalopathy syndrome 23.87 22.18 33 24027 33828 110531411
Arthritis 23.64 22.18 4 24056 167582 110397657
Fungal oesophagitis 23.57 22.18 9 24051 1132 110564107
Cryptosporidiosis infection 23.55 22.18 9 24051 1134 110564105
Dehydration 23.49 22.18 16 24044 279495 110285744
Oral disorder 23.34 22.18 20 24040 11983 110553256
Vascular device infection 23.30 22.18 23 24037 16489 110548750
Mixed liver injury 23.23 22.18 20 24040 12059 110553180
Gastrointestinal disorder 22.93 22.18 12 24048 241940 110323299
Fluorosis 22.90 22.18 6 24054 219 110565020
Hypoxia 22.83 22.18 71 23989 129444 110435795
Somnolence 22.47 22.18 19 24041 297430 110267809
Myocardial infarction 22.31 22.18 7 24053 192076 110373163
Cytopenia 22.21 22.18 30 24030 30086 110535153

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cholestasis 20.19 18.94 3 3 31 113916

Pharmacologic Action:

SourceCodeDescription
ATC J02AX05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
Other antimycotics for systemic use
FDA CS M0519359 Lipopeptides
FDA EPC N0000175507 Echinocandin Antifungal
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
CHEBI has role CHEBI:35718 antifungal agent
CHEBI has role CHEBI:35441 antiinfective agent

Related Drugs by ATC class:

J02AX Other antimycotics for systemic use 5 drugs
anidulafungincaspofunginflucytosineibrexafungerprezafungin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Candidiasis of the esophagus indication 20639004 DOID:13146
Disseminated candidiasis indication 70572005
Candidal septicemia indication 187022007
Candidemia indication 432261003
Prevention of Disseminated Candidiasis indication
Candida Peritonitis indication
Oropharyngeal Candidiasis off-label use
Intravascular hemolysis contraindication 15601008
Kidney disease contraindication 90708001 DOID:557
Liver function tests abnormal contraindication 166603001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.09 acidic
pKa2 10.7 acidic
pKa3 12.91 acidic
pKa4 13.44 acidic
pKa5 13.52 acidic
pKa6 13.9 acidic
pKa7 13.91 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
ATP-binding cassette sub-family G member 2 Transporter IC50 4.68 CHEMBL
Beta-1,3-glucan synthase catalytic subunit 1 Enzyme INHIBITOR CHEMBL CHEMBL
Beta-1,3-glucan synthase Enzyme WOMBAT-PK

External reference:

IDSource
D02465 KEGG_DRUG
208538-73-2 SECONDARY_CAS_RN
4024920 VANDF
4024948 VANDF
C1120386 UMLSCUI
CHEBI:600520 CHEBI
CHEMBL457547 ChEMBL_ID
CHEMBL1237070 ChEMBL_ID
D000077551 MESH_DESCRIPTOR_UI
DB01141 DRUGBANK_ID
8069 INN_ID
R10H71BSWG UNII
477468 PUBCHEM_CID
325887 RXNORM
19567 MMSL
334346 MMSL
42868 MMSL
66902 MMSL
d05487 MMSL
010714 NDDF
010715 NDDF
416127003 SNOMEDCT_US
416233001 SNOMEDCT_US
426226002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9361 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 28 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9362 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 28 sections
Micafungin in Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-9051 INJECTION 50 mg INTRAVENOUS NDA 28 sections
Micafungin in Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-9053 INJECTION 100 mg INTRAVENOUS NDA 28 sections
Micafungin in Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0338-9055 INJECTION 150 mg INTRAVENOUS NDA 28 sections
Mycamine HUMAN PRESCRIPTION DRUG LABEL 1 0469-3211 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS NDA 27 sections
Mycamine HUMAN PRESCRIPTION DRUG LABEL 1 0469-3250 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 27 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 25021-190 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 32 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 25021-191 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 32 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 42023-229 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 26 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 42023-230 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS NDA 26 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 42658-022 INJECTION, POWDER, FOR SOLUTION 50 mg INTRAVENOUS ANDA 17 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 42658-023 INJECTION, POWDER, FOR SOLUTION 100 mg INTRAVENOUS ANDA 17 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 63323-728 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 30 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 63323-728 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 30 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 63323-729 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 30 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 63323-729 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 30 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 63323-729 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 30 sections
MICAFUNGIN HUMAN PRESCRIPTION DRUG LABEL 1 67184-0589 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS ANDA 26 sections
MICAFUNGIN HUMAN PRESCRIPTION DRUG LABEL 1 67184-0590 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 26 sections
MICAFUNGIN HUMAN PRESCRIPTION DRUG LABEL 1 68462-771 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS ANDA 26 sections
MICAFUNGIN HUMAN PRESCRIPTION DRUG LABEL 1 68462-772 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 26 sections
MICAFUNGIN HUMAN PRESCRIPTION DRUG LABEL 1 70377-075 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS ANDA 26 sections
MICAFUNGIN HUMAN PRESCRIPTION DRUG LABEL 1 70377-076 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 26 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 70710-1724 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS ANDA 27 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 70710-1725 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 27 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 70771-1683 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS ANDA 1 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 70771-1684 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 1 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 71288-028 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 30 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 71288-029 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 30 sections